38 research outputs found
Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood
Get PDFEdoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
Full text link
Response of authors to Ganju and Dias' comments on 'Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful' by D. A. Parasrampuria and L. Z. Benet
No full textRecommended from our members
Response of authors to Ganju and Dias' comments on 'Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful' by D. A. Parasrampuria and L. Z. Benet
No full textResponse of authors to Ganju and Dias’ comments on ‘Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful’ by D. A. Parasrampuria and L. Z. B
No full textImplications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice
No full text
Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis
No full textPharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital
No full text
